Cargando…

Immunomodulatory Effects of IFNα on T and NK Cells in Chronic Myeloid Leukemia Patients in Deep Molecular Response Preparing for Treatment Discontinuation

A deep and stable molecular response (DMR) is a prerequisite for a successful treatment-free remission (TFR) in chronic myeloid leukemia (CML). In order to better identify and analyze potential candidates of successful TFR, we examined the phenotypic and functional host immune compartment in DMR pat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Puzzolo, Maria Cristina, Breccia, Massimo, Mariglia, Paola, Colafigli, Gioia, Pepe, Sara, Scalzulli, Emilia, Mariggiò, Elena, Latagliata, Roberto, Guarini, Anna, Foà, Robin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9570842/ https://www.ncbi.nlm.nih.gov/pubmed/36233461 http://dx.doi.org/10.3390/jcm11195594

Ejemplares similares

Insights into the optimal use of ponatinib in patients with chronic phase chronic myeloid leukaemia
por: Molica, Matteo, et al.
Publicado: (2019)

Prognostic factors associated with a stable MR4.5 achievement in chronic myeloid leukemia patients treated with imatinib
por: Breccia, Massimo, et al.
Publicado: (2017)

Cutaneous Lesions Anticipating Accelerated Phase of Multidrug Resistant Chronic Myeloid Leukemia Responsive to Ponatinib
por: Breccia, Massimo, et al.
Publicado: (2016)

Treatment discontinuation following low-dose TKIs in 248 chronic myeloid leukemia patients: Updated results from a campus CML real-life study
por: Iurlo, A., et al.
Publicado: (2023)

Management of Acute Promyelocytic Leukemia in the Elderly
por: Lo-Coco, Francesco, et al.
Publicado: (2013)

TH2/TH1 Shift Under Ibrutinib Treatment in Chronic Lymphocytic Leukemia
por: Puzzolo, Maria Cristina, et al.
Publicado: (2021)

Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia
por: Ilander, M, et al.
Publicado: (2017)

Bosutinib for Chronic Myeloid Leukemia
por: Breccia, Massimo, et al.
Publicado: (2015)

Chronic myeloid leukemia management at the time of the COVID-19 pandemic in Italy. A campus CML survey
por: Breccia, Massimo, et al.
Publicado: (2020)

Case Report: Avelumab and ruxolitinib to manage polycythemia vera and secondary metastatic Merkel cell carcinoma: a possible successful combination
por: Masucci, Chiara, et al.
Publicado: (2023)

Low Incidence Rate of Opportunistic and Viral Infections During Imatinib Treatment in Chronic Myeloid Leukemia Patients in Early and Late Chronic Phase.
por: Breccia, Massimo, et al.
Publicado: (2011)

Interferon (IFN)-λ Takes the Helm: Immunomodulatory Roles of Type III IFNs
por: Zanoni, Ivan, et al.
Publicado: (2017)

RR6 prognostic model provides information about survival for myelofibrosis treated with ruxolitinib: validation in a real-life cohort
por: Scalzulli, Emilia, et al.
Publicado: (2022)

Case Report: Infectious prophylaxis in hematological malignancies
por: Passucci, Mauro, et al.
Publicado: (2023)

Observational study of chronic myeloid leukemia Italian patients who discontinued tyrosine kinase inhibitors in clinical practice
por: Fava, Carmen, et al.
Publicado: (2019)

Evaluation of the Immunomodulatory Activity of the Chicken NK-Lysin-Derived Peptide cNK-2
por: Kim, Woo H., et al.
Publicado: (2017)

Chronic Myeloid Leukemia Data at ASH 2021: A Podcast on Patient Unmet Needs and Later-Line Treatment Developments
por: Breccia, Massimo
Publicado: (2022)

IFN type III: in vivo NK cell response
por: Souza-Fonseca-Guimaraes, Fernando, et al.
Publicado: (2015)

Imatinib improved the overall survival of chronic myeloid leukemia patients in low- and middle-income countries: A therapeutic goal has been reached
por: Breccia, Massimo
Publicado: (2020)

Mitochondrial CMPK2 mediates immunomodulatory and antiviral activities through IFN-dependent and IFN-independent pathways
por: Lai, Jenn-Haung, et al.
Publicado: (2021)

Systematic review of dasatinib in chronic myeloid leukemia
por: Breccia, Massimo, et al.
Publicado: (2013)

Refining targeted therapies in chronic myeloid leukemia: development and application of nilotinib, a step beyond imatinib
por: Breccia, Massimo, et al.
Publicado: (2008)

Immunomodulatory Role of NK Cells during Antiviral Antibody Therapy
por: Naranjo-Gomez, Mar, et al.
Publicado: (2021)

Prognostic Significance of Transcript-Type BCR - ABL1 in Chronic Myeloid Leukemia
por: Molica, Matteo, et al.
Publicado: (2020)

Lipopolysaccharide induces IFN-γ production in human NK cells
por: Kanevskiy, Leonid M., et al.
Publicado: (2013)

CD160 is essential for NK-mediated IFN-γ production
por: Tu, Tony C., et al.
Publicado: (2015)

IFN-γ modulates Ly-49 receptors on NK cells in IFN-γ-induced pregnancy failure
por: Li, Zhong-Yin, et al.
Publicado: (2015)

Immunomodulatory potential of anti-IFN-beta antibodies on monocyte-derived macrophages
por: Sominanda, Ajith, et al.
Publicado: (2023)

NK-, NKT- and CD8-Derived IFNγ Drives Myeloid Cell Activation and Erythrophagocytosis, Resulting in Trypanosomosis-Associated Acute Anemia
por: Cnops, Jennifer, et al.
Publicado: (2015)

A Retrospective Analysis about Frequency of Monitoring in Italian Chronic Myeloid Leukemia Patients after Discontinuation
por: Dragani, Matteo, et al.
Publicado: (2020)

Modulated expression of adhesion, migration and activation molecules may predict the degree of response in chronic lymphocytic leukemia patients treated with ibrutinib plus rituximab
por: Peragine, Nadia, et al.
Publicado: (2020)

Concerted action of IFN-α and IFN-λ induces local NK cell immunity and halts cancer growth
por: Lasfar, Ahmed, et al.
Publicado: (2016)

Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real‐life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart
por: Caocci, Giovanni, et al.
Publicado: (2019)

Genomic scale analysis of NK cells impact on response to IFN-α
por: Ascierto, Maria L, et al.
Publicado: (2013)

Is IFN expression by NK cells a hallmark of severe COVID-19?
por: Csordas, Bárbara Guimarães, et al.
Publicado: (2022)

Immunomodulatory Drugs in Acute Myeloid Leukemia Treatment
por: Piccolomo, Antonio, et al.
Publicado: (2020)

Dose Optimization of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: A New Therapeutic Challenge
por: Iurlo, Alessandra, et al.
Publicado: (2021)

Type I IFN promotes NK cell expansion during viral infection by protecting NK cells against fratricide
por: Madera, Sharline, et al.
Publicado: (2016)

Genome-Wide CRISPR Screen Reveals Cancer Cell Resistance to NK Cells Induced by NK-Derived IFN-γ
por: Zhuang, Xiaoxuan, et al.
Publicado: (2019)

Enlarged Memory T-Cell Pool and Enhanced Th1-Type Responses in Chronic Myeloid Leukemia Patients Who Have Successfully Discontinued IFN-α Monotherapy
por: Ilander, Mette, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_dd0v66aoatigc0r08ghsr0rrci